Clinical Trials · NCT07325435
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
- Phase
- Phase 4
- Recruitment status
- Active Not Recruiting
- Sponsor
- MaryAnn Banerji
- Enrollment
- 60
- Start date
- Dec 2024
- Locations
- 1 site, United States
- Primary endpoint
- Change in Stimulated C-peptide Index during an Oral Glucose Tolerance Test is a measure of Beta Cell Function and will be measuresd at baseline and at 16 weeks after treatment with GLP-1 Receptor Agonist or SGLT2-Inhibitor